{"product_id":"spro-vrio-analysis","title":"Spero Therapeutics, Inc. (SPRO): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlocking the secrets to Spero Therapeutics, Inc. (SPRO)'s market dominance starts here: this VRIO analysis cuts straight to the core, assessing whether its resources are truly Valuable, Rare, Inimitable, and Organized for lasting competitive advantage. The distilled summary in \u0026amp;O4\u0026amp; reveals the critical findings - read on immediately to see precisely where Spero Therapeutics, Inc. (SPRO) stands against its rivals.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSpero Therapeutics, Inc. (SPRO) - VRIO Analysis: First Core Capabilities \/ Resources: Tebipenem HBr Phase 3 Efficacy Data \u0026amp; NDA Readiness\n\u003c\/h2\u003e\n\u003cp\u003eYou’re looking at the core asset that could redefine outpatient care for serious infections. The successful Phase 3 PIVOT-PO data for Tebipenem HBr is the linchpin for Spero Therapeutics right now, given the partnership with GSK. Honestly, this data package is what separates them from many peers.\u003c\/p\u003e\n\u003cp\u003eThe key takeaway is that the non-inferiority data against IV imipenem-cilastatin, presented in October 2025, positions Tebipenem HBr to potentially become the first oral carbapenem in the US, addressing an estimated 2.9 million annual cUTI cases.\u003c\/p\u003e\n\n\u003ch3\u003eVRIO Framework Assessment for Tebipenem HBr Data Package\u003c\/h3\u003e\n\u003cp\u003eHere’s the quick math on how this resource scores against the VRIO criteria. The competitive advantage is real, but it’s a race against the clock until approval.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n\u003ctd\u003eScore\u003c\/td\u003e\n\u003ctd\u003eJustification Based on 2025 Data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue (V)\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eMeets primary endpoint: 58.5% overall response vs. 60.2% for IV standard of care. Offers first oral carbapenem option.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity (R)\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003ePositive Phase 3 data for a novel oral carbapenem against cUTI is exceptionally rare in this space.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability (I)\u003c\/td\u003e\n\u003ctd\u003eLow\u003c\/td\u003e\n\u003ctd\u003eCompetitors cannot replicate this specific, successful clinical trial outcome (PIVOT-PO, N=1,690).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization (O)\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eGSK plans to submit the NDA in Q4 2025; Spero anticipates a regulatory decision in 2H 2026.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eTemporary\u003c\/td\u003e\n\u003ctd\u003eAdvantage lasts until regulatory approval, after which it becomes a commercial product with established market position.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eValue: The Clinical Proof Point\u003c\/h3\u003e\n\u003cp\u003eThe value is undeniable. The PIVOT-PO trial confirmed non-inferiority to the intravenous (IV) gold standard, imipenem-cilastatin. Specifically, the overall response rate was 58.5% for oral Tebipenem HBr versus 60.2% for the IV drug, a difference of only -1.3%.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePotential to reduce hospital stays.\u003c\/li\u003e\n\u003cli\u003eAddresses a market contributing over $6 billion in US healthcare costs annually.\u003c\/li\u003e\n\u003cli\u003eClinical cure rates were 93.5% for Tebipenem HBr.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis shifts treatment from the hospital setting to the home, which is a massive value driver for payers and patients.\u003c\/p\u003e\n\n\u003ch3\u003eRarity and Imitability: The Barrier to Entry\u003c\/h3\u003e\n\u003cp\u003eThe rarity stems from the difficulty of developing a successful carbapenem that is orally bioavailable. To be fair, this isn't just about having a molecule; it's about having the specific, positive data from the 1,690-patient PIVOT-PO trial.\u003c\/p\u003e\n\u003cp\u003eImitability is low because competitors can’t just rerun the trial; they have to replicate the exact clinical success, which is a high bar. Still, once approved, other companies will pivot R\u0026amp;D to find the next best oral agent.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization: Executing the Filing\u003c\/h3\u003e\n\u003cp\u003eThe organization component hinges on the partnership execution. Spero Therapeutics has the responsibility to enable the filing, and GSK, the commercialization partner, is set to file the New Drug Application (NDA) with the FDA in Q4 2025.\u003c\/p\u003e\n\u003cp\u003eThe company’s financial footing supports this final push; Spero reported a net loss of $7.4 million in Q3 2025, but their cash position of $48.6 million as of September 30, 2025, is estimated to last into 2028. This runway gives them time past the anticipated regulatory decision in 2H 2026.\u003c\/p\u003e\n\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSpero Therapeutics, Inc. (SPRO) - VRIO Analysis: Second Core Capabilities \/ Resources: GSK Commercialization Partnership for Tebipenem HBr\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue: Very High\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe partnership de-risks commercialization by shifting development and sales costs to GSK for most territories. It secures future revenue streams through upfront payments, milestones, and royalties.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eUpfront Payment Received: \u003cstrong\u003e$66 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eEquity Investment: GSK purchased \u003cstrong\u003e7,450,000\u003c\/strong\u003e shares for approximately \u003cstrong\u003e$9 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash Runway Impact: The \u003cstrong\u003e$66 million\u003c\/strong\u003e upfront payment is expected to fund the company beyond \u003cstrong\u003e2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eRarity: Medium\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eWhile large pharmaceutical partnerships are common, securing an exclusive, late-stage deal for a potentially first-in-class oral carbapenem is significant.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability: Medium\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe specific financial terms, including the royalty structure and the division of development responsibilities, are unique to this agreement.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization: High\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe partnership structure clearly defines responsibilities for ongoing development and commercialization activities.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSpero Responsibility: Execution and costs of the follow-up Phase 3 clinical trial.\u003c\/li\u003e\n\u003cli\u003eGSK Responsibility: Execution and costs of additional development, including Phase III regulatory filing and commercialization activities outside the retained Asian territories.\u003c\/li\u003e\n\u003cli\u003eRegulatory Timeline: New NDA submission expected in the second half of \u003cstrong\u003e2025\u003c\/strong\u003e, with potential approval mid-\u003cstrong\u003e2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Sustained\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAs long as the license agreement remains in force, this structure provides a sustained advantage over unpartnered assets by leveraging GSK's global commercial reach and absorbing post-Phase 3 risk.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Component\u003c\/td\u003e\n\u003ctd\u003eAmount \/ Structure\u003c\/td\u003e\n\u003ctd\u003eNotes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUpfront Payment\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$66 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eReceived upon closing of the agreement.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEquity Investment\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eGSK purchased \u003cstrong\u003e7,450,000\u003c\/strong\u003e shares at approximately \u003cstrong\u003e$1.20805\u003c\/strong\u003e per share.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Potential Milestones\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$525 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eDevelopment, sales, and commercial milestones.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecific Milestones (Partial)\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$400 million\u003c\/strong\u003e detailed\u003c\/td\u003e\n\u003ctd\u003eIncludes \u003cstrong\u003e$175 million\u003c\/strong\u003e triggered by approval and \u003cstrong\u003e$225 million\u003c\/strong\u003e in sales milestones.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalty Rates (Net Sales)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eLow-single digit to low-double digit\u003c\/strong\u003e tiered\u003c\/td\u003e\n\u003ctd\u003eApplies to net product sales outside of retained territories.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSublicensing Fees (Meiji Seika)\u003c\/td\u003e\n\u003ctd\u003eLow double digits, capped at \u003cstrong\u003e$7.5 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eFees related to the license from Meiji Seika.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eSpero Therapeutics, Inc. (SPRO) - VRIO Analysis: Third Core Capabilities \/ Resources: Financial Runway Extending into 2028\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Component\u003c\/th\u003e\n\u003cth\u003eAssessment\u003c\/th\u003e\n\u003cth\u003eSupporting Data\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eOperational funding extends into \u003cstrong\u003e2028\u003c\/strong\u003e based on \u003cstrong\u003e$48.6 million\u003c\/strong\u003e cash (as of \u003cstrong\u003eSep 30, 2025\u003c\/strong\u003e) plus expected milestones.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eMedium\u003c\/td\u003e\n\u003ctd\u003eExtended runway is a strong position for a clinical-stage company, but not entirely unique.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInimitability\u003c\/td\u003e\n\u003ctd\u003eLow\u003c\/td\u003e\n\u003ctd\u003eCash is fungible; however, securing non-dilutive milestones, such as the \u003cstrong\u003e$23.8 million\u003c\/strong\u003e earned from GSK in \u003cstrong\u003eAugust 2025\u003c\/strong\u003e, is difficult to replicate.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eManagement demonstrated burn rate control, evidenced by the reduced \u003cstrong\u003eQ3 2025\u003c\/strong\u003e net loss of \u003cstrong\u003e$7.4 million\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eTemporary\u003c\/td\u003e\n\u003ctd\u003eAdvantage is time-based and erodes as operational cash is utilized.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\n\u003cstrong\u003eFinancial Metrics Supporting Runway and Burn Management:\u003c\/strong\u003e\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash and cash equivalents as of \u003cstrong\u003eSeptember 30, 2025\u003c\/strong\u003e: \u003cstrong\u003e$48.6 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eEstimated financial runway: Extends into \u003cstrong\u003e2028\u003c\/strong\u003e based on current cash and operating plan.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eQ3 2025\u003c\/strong\u003e Net Loss: \u003cstrong\u003e$7.4 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eQ3 2024\u003c\/strong\u003e Net Loss: \u003cstrong\u003e$17.1 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eDiluted Net Loss Per Share for \u003cstrong\u003eQ3 2025\u003c\/strong\u003e: \u003cstrong\u003e$0.13\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eDiluted Net Loss Per Share for \u003cstrong\u003eQ3 2024\u003c\/strong\u003e: \u003cstrong\u003e$0.32\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\n\u003cstrong\u003eThird Quarter \u003cstrong\u003e2025\u003c\/strong\u003e Operating Expenses and Revenue:\u003c\/strong\u003e\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eCategory\u003c\/th\u003e\n\u003cth\u003eQ3 2025 Amount\u003c\/th\u003e\n\u003cth\u003eQ3 2024 Amount\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$13.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch and Development Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$8.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$26.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeneral and Administrative Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eThe decrease in Research and Development expenses from \u003cstrong\u003eQ3 2024\u003c\/strong\u003e to \u003cstrong\u003eQ3 2025\u003c\/strong\u003e was primarily due to reduced clinical expenses related to the PIVOT-PO Trial and lower expenses on the SPR720 clinical program.\u003c\/li\u003e\n\u003cli\u003eThe decrease in General and Administrative expenses from \u003cstrong\u003eQ3 2024\u003c\/strong\u003e to \u003cstrong\u003eQ3 2025\u003c\/strong\u003e was primarily due to a decrease in personnel-related costs.\u003c\/li\u003e\n\u003cli\u003eThe \u003cstrong\u003eSPR720\u003c\/strong\u003e program was discontinued in \u003cstrong\u003eQ3 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eGSK plans to submit data from the PIVOT-PO trial as part of a planned US Food and Drug Administration (FDA) filing in \u003cstrong\u003e4Q 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\n\u003cbr\u003e\u003ch2\u003eSpero Therapeutics, Inc. (SPRO) - VRIO Analysis: Fourth Core Capabilities \/ Resources: The 'Potential Platform' Technology\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue: Medium\u003c\/strong\u003e; This proprietary science, the Potentiator Platform, is designed to expand the potency of existing antibiotics against Gram-negative bacteria by disrupting the outer cell membrane.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity: High\u003c\/strong\u003e; A novel, proprietary platform technology targeting the Gram-negative outer membrane is inherently rare in the market.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability: Medium\u003c\/strong\u003e; Platform science is complex, but competitors can develop alternative technologies over time. The platform has yielded multiple molecules.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization: Medium\u003c\/strong\u003e; The platform underpins future discovery efforts, evidenced by continued investment. Research and development expenses for the third quarter of 2025 were $8.6 million.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Temporary\u003c\/strong\u003e; Value is latent until a new candidate from the platform successfully enters or completes clinical trials. The cash position as of September 30, 2025, was $48.6 million, intended to fund operations into 2028.\u003c\/p\u003e\n\u003cp\u003eThe platform's output, such as SPR206, is designed to treat Multi-Drug Resistant (MDR) Gram-Negative bacterial infections in the hospital setting.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003ePlatform Component\u003c\/th\u003e\n\u003cth\u003eAssociated Candidate\u003c\/th\u003e\n\u003cth\u003eTarget Pathogens\u003c\/th\u003e\n\u003cth\u003ePreclinical\/Historical Data Point\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePotentiator Platform (Mechanism)\u003c\/td\u003e\n\u003ctd\u003eSPR741 (Lead Candidate)\u003c\/td\u003e\n\u003ctd\u003eMDR E. coli, K. pneumoniae, A. baumannii\u003c\/td\u003e\n\u003ctd\u003eDemonstrated reduced required doses of antibiotics like azithromycin and meropenem.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIV Potentiator Platform\u003c\/td\u003e\n\u003ctd\u003eSPR206\u003c\/td\u003e\n\u003ctd\u003eMDR Gram-Negative, including Acinetobacter baumannii and Pseudomonas aeruginosa\u003c\/td\u003e\n\u003ctd\u003eCompleted a preclinical toxicology study in accordance with Good Laboratory Practice (GLP) requirements.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eKey statistical and financial data points related to the platform's development focus:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eResearch and development expenses for the third quarter of 2024 were $23.7 million.\u003c\/li\u003e\n\u003cli\u003eSPR206 is designed to treat MDR Gram-negative bacterial infections as a monotherapy.\u003c\/li\u003e\n\u003cli\u003eThe platform's initial lead candidate, SPR741, showed in studies that adding it effectively reduced the doses of antibiotics required to inhibit bacterial growth.\u003c\/li\u003e\n\u003cli\u003eThe company reported a net loss of $7.4 million for the third quarter of 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSpero Therapeutics, Inc. (SPRO) - VRIO Analysis: Fifth Core Capabilities \/ Resources: SPR206 Asset and Pfizer Licensing Structure\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue: Medium\u003c\/strong\u003e; SPR206 is an IV polymyxin candidate for MDR Gram-negative infections, validated by a prior equity investment and licensing deal with Pfizer. The asset holds Qualified Infectious Disease Product (QIDP) designation from the FDA for cUTI and HABP\/VABP. Phase 1 data showed the candidate was generally well tolerated with no evidence of nephrotoxicity at anticipated therapeutic doses. Phase 1 BAL trial data indicated lung exposures consistent with predicted therapeutic levels, with a mean lung ELF to plasma AUC ratio of 0.264 at 100 mg administered three times daily.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity: Medium\u003c\/strong\u003e; Next-gen polymyxins are being developed by several firms, but the Pfizer relationship is unique. This relationship includes a $40 million equity investment from Pfizer in June 2021. Select SPR206 studies also receive funding support from the U.S. Department of Defense (Award No. W81XWH-1910295) and up to $23 million from the National Institute of Allergy and Infectious Diseases (NIAID).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability: Medium\u003c\/strong\u003e; The specific IP and deal structure are not easily copied. The licensing agreement grants Pfizer rights in ex-U.S. and ex-Asia territories.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization: Medium\u003c\/strong\u003e; The program's focus has clearly shifted to support Tebipenem HBr, but the asset remains with an IND cleared for a Phase 2 trial in HABP\/VABP, contingent on non-dilutive funding availability.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Temporary\u003c\/strong\u003e; Value is tied to SPR206's clinical progress, which is currently secondary.\u003c\/p\u003e\n\u003cp\u003eThe key financial and structural terms of the Pfizer licensing agreement are summarized below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eParameter\u003c\/th\u003e\n\u003cth\u003eValue\/Detail\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePfizer Equity Investment Amount\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$40 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePfizer Share Purchase Price\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$16.93\u003c\/strong\u003e per share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensed Territories (Pfizer)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eex-U.S. and ex-Asia\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMaximum Milestone Payments to Spero\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$80 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalty Rate (Net Sales in Licensed Territories)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eHigh single digit to low double-digit\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA Designation\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eQIDP\u003c\/strong\u003e for cUTI and HABP\/VABP\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 1 BAL Dosing\/Exposure\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e100 mg\u003c\/strong\u003e three times daily; ELF\/Plasma AUC ratio of \u003cstrong\u003e0.264\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eAdditional external funding sources supporting SPR206 development include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eU.S. Department of Defense (DoD) Award Number: \u003cstrong\u003eW81XWH-1910295\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eNational Institute of Allergy and Infectious Diseases (NIAID) award of up to \u003cstrong\u003e$23 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSpero Therapeutics, Inc. (SPRO) - VRIO Analysis: Sixth Core Capabilities \/ Resources: Intellectual Property Rights for Key Candidates\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e High\u003c\/p\u003e\n\u003cp\u003eExclusive rights to develop and commercialize key molecules like Tebipenem HBr (ex-Asia) and SPR206 provide market exclusivity.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High\u003c\/p\u003e\n\u003cp\u003eGranted patents and exclusive licenses are legally protected barriers to entry.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low\u003c\/p\u003e\n\u003cp\u003eCompetitors cannot legally use these specific compounds without licensing.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High\u003c\/p\u003e\n\u003cp\u003eIP is actively managed through licensing agreements with GSK and Meiji Seika Pharma Co. Ltd.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained\u003c\/p\u003e\n\u003cp\u003ePatent protection offers the longest-lasting form of competitive advantage.\u003c\/p\u003e\n\u003cp\u003eTebipenem HBr Intellectual Property and Collaboration Financials:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial\/Milestone Term\u003c\/td\u003e\n\u003ctd\u003eData Point\u003c\/td\u003e\n\u003ctd\u003eReference\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGSK Upfront Payment\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$66 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Potential Milestone Payments (from GSK)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eup to $525 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGSK Equity Investment Amount\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGSK Stock Purchase Price Per Share\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.20805\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGSK Shares Purchased\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e7,450,000 shares\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalty Rate on Net Product Sales (GSK Territory)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eLow-single digit to low-double digit tiered\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTerritories Retained by Meiji Seika\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eJapan and certain other Asian countries\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eTebipenem HBr Development Milestones:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePIVOT-PO Phase 3 trial enrollment began in \u003cstrong\u003eJanuary 2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eIDMC recommended stopping the PIVOT-PO trial early for efficacy in \u003cstrong\u003eMay 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eOral Tebipenem HBr overall success rate in PIVOT-PO: \u003cstrong\u003e58.5%\u003c\/strong\u003e (261\/446 participants).\u003c\/li\u003e\n\u003cli\u003eComparator IV imipenem-cilastatin overall success rate in PIVOT-PO: \u003cstrong\u003e60.2%\u003c\/strong\u003e (291\/483 participants).\u003c\/li\u003e\n\u003cli\u003eGSK plans to submit data for planned US FDA filing in \u003cstrong\u003e2H 2025\u003c\/strong\u003e (or \u003cstrong\u003e4Q 2025\u003c\/strong\u003e).\u003c\/li\u003e\n\u003cli\u003eAnticipated regulatory decision: \u003cstrong\u003e2H 2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eSPR206 is an IV-administered next-generation polymyxin product candidate developed from the potentiator platform for MDR Gram-negative infections.\u003c\/p\u003e\n\u003cp\u003eCompany Financial Context:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash and cash equivalents as of \u003cstrong\u003eSeptember 30, 2025\u003c\/strong\u003e: \u003cstrong\u003e$48.6 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eEstimate for funding operations into \u003cstrong\u003e2028\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCurrent Assets as of fiscal year ending \u003cstrong\u003e2024-12-31\u003c\/strong\u003e: \u003cstrong\u003e$107.28M\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSpero Therapeutics, Inc. (SPRO) - VRIO Analysis: Seventh Core Capabilities \/ Resources: Clinical\/Regulatory Execution Capability\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue: High\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDemonstrated ability to successfully run a pivotal Phase 3 trial (PIVOT-PO) that met its primary endpoint and was stopped early for efficacy.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eTebipenem HBr Result\u003c\/th\u003e\n\u003cth\u003eComparator (IV Imipenem-cilastatin) Result\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOverall Success Rate (Primary Endpoint)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e58.5%\u003c\/strong\u003e (261\/446 participants)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e60.2%\u003c\/strong\u003e (291\/483 participants)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical Cure Rate (Secondary)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e93.5%\u003c\/strong\u003e (417\/446)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e95.2%\u003c\/strong\u003e (460\/483)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMicrobiological Response Rate (Secondary)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e60.3%\u003c\/strong\u003e (269\/446)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e61.3%\u003c\/strong\u003e (296\/483)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity: Medium\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSuccessfully navigating a pivotal trial to a positive readout is a high bar in biotech.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe PIVOT-PO trial was stopped early for efficacy in May 2025 following an Independent Data Monitoring Committee recommendation.\u003c\/li\u003e\n\u003cli\u003eThe trial demonstrated non-inferiority based on a 10% noninferiority margin.\u003c\/li\u003e\n\u003cli\u003eComplicated UTIs (cUTIs) represent an estimated 2.9 million cases treated annually in the U.S., contributing to over $6 billion per year in healthcare costs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability: Medium\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eProcesses can be copied, but the specific team experience is not easily transferred.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe successful execution involved collaboration with GSK, which now plans to submit data for US regulatory filing in Q4 2025.\u003c\/li\u003e\n\u003cli\u003eTebipenem HBr previously received Qualified Infectious Disease Product (QIDP) and Fast Track designations from the US FDA.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization: High\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis success validates the internal operational structure for late-stage development.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe biotech utilized the upfront payment from the GSK licensing deal, which was $66 million, to fund the Phase 3 trial.\u003c\/li\u003e\n\u003cli\u003eThe early stop reduced Spero's costs, adjusting the aggregate potential commercial milestone payments contingent upon first sales from up to $150.0 million to up to $101.0 million.\u003c\/li\u003e\n\u003cli\u003eResearch and development expenses for Q2 2025 were $10.7 million, compared to $23.7 million in Q2 2024, primarily due to reduced clinical expenses related to the PIVOT-PO trial.\u003c\/li\u003e\n\u003cli\u003eExisting cash and milestone payments provide an anticipated runway to fund operating expenses into 2028.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Temporary\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eMust be continually proven with subsequent successful filings and trials.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSpero Therapeutics, Inc. (SPRO) - VRIO Analysis: Eighth Core Capabilities \/ Resources: Strategic Focus on MDR\/Rare Disease Therapeutics\n\u003c\/h2\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eMedium; Targeting areas with high unmet medical need often allows for faster regulatory pathways and premium pricing.\u003c\/p\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eLow; Many biotechs focus on these areas, especially anti-infectives.\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eLow; A strategic focus is easy for others to adopt.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eHigh; The company has streamlined operations by discontinuing the SPR720 program in Q3 2025 to concentrate resources.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eDiscontinued SPR720 program in Q3 2025 following Phase 2a review for NTM-PD.\u003c\/li\u003e\n\u003cli\u003eResearch and development expenses for Q3 2025 were $8.6 million, compared to $26.9 million for Q3 2024.\u003c\/li\u003e\n\u003cli\u003eGeneral and administrative expenses for Q3 2025 were $4.2 million, compared to $5.2 million for Q3 2024.\u003c\/li\u003e\n\u003cli\u003eAs of September 30, 2025, cash and cash equivalents were $48.6 million.\u003c\/li\u003e\n\u003cli\u003eEstimated cash runway to fund operations into 2028.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Metric (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003ctd\u003eComparison (Q3 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCompared to $13.5 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCompared to $17.1 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiluted Net Loss Per Share\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.13\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCompared to $0.32\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eNone; This is a market choice, not a unique internal resource.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTebipenem HBr Phase 3 PIVOT-PO oral 600 mg overall success rate: 58.5% (261\/446 participants).\u003c\/li\u003e\n\u003cli\u003eTebipenem HBr comparator (IV imipenem-cilastatin 500 mg) overall success rate: 60.2% (291\/483 participants).\u003c\/li\u003e\n\u003cli\u003eTebipenem HBr development eligible for up to $400 million in milestone payments from GSK, plus tiered royalties.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSpero Therapeutics, Inc. (SPRO) - VRIO Analysis: Ninth Core Capabilities \/ Resources: Management Team's Experience in Drug Development\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e: High; Experienced leadership, like CEO Esther Rajavelu, who also serves as CFO, guides capital allocation and partnership management.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e: Medium; Experienced pharma executives are valuable but can be poached by competitors.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e: Medium; While individuals can be hired, the team's specific history together is harder to replicate.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e: High; The team is currently executing the critical Tebipenem HBr filing strategy.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: Temporary; Depends on the tenure and continued performance of key personnel.\u003c\/p\u003e\n\n\u003cp\u003eFinance: Update the 13-week cash flow model to reflect the Q3 \u003cstrong\u003e\\$48.6 million\u003c\/strong\u003e cash balance and the expected GSK filing milestone timing.\u003c\/p\u003e\n\n\u003cp\u003eThe current financial position and partnership execution metrics are summarized below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eContext\/Timing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents (Ending Balance)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$48.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of September 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExpected FDA Filing Window (Tebipenem HBr)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2H 2025\u003c\/strong\u003e or \u003cstrong\u003e4Q 2025\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eWith GSK\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinal Development Milestone Received from GSK\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$23.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eReceived in August 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Potential Milestones from GSK (Tebipenem HBr)\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e\\$351 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eTied to the oral antibiotic program\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTebipenem HBr Overall Success Rate (vs. IV Control)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e58.5%\u003c\/strong\u003e vs. \u003cstrong\u003e60.2%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003ePIVOT-PO Phase 3 primary endpoint data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe management team's execution is further evidenced by the following operational and financial data points:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe PIVOT-PO trial met its primary endpoint for \u003cstrong\u003eTebipenem HBr\u003c\/strong\u003e efficacy.\u003c\/li\u003e\n\u003cli\u003eThe anticipated cash runway, including non-contingent milestones, extends into \u003cstrong\u003e2028\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe initial upfront payment from the \u003cstrong\u003eGSK\u003c\/strong\u003e license agreement was \u003cstrong\u003e\\$66 million\u003c\/strong\u003e (in 2022).\u003c\/li\u003e\n\u003cli\u003eThe first tranche of the \u003cstrong\u003e\\$95 million\u003c\/strong\u003e development milestone from GSK was \u003cstrong\u003e\\$23.8 million\u003c\/strong\u003e, received in Q1 2024 (based on 2023 data).\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516255690901,"sku":"spro-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/spro-vrio-analysis.png?v=1740217202","url":"https:\/\/dcf-model.com\/pt\/products\/spro-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}